Analysts’ Viewpoint on The Market Scenario
Research and development in the drug discovery platforms and collaborative efforts of healthcare professionals & governments to introduce drugs are driving the global pulmonary arterial hypertension (PAH) market amid the coronavirus pandemic.
Companies in the global market are accelerating their product development and leveraging revenue opportunities to gain edge over competitors. Market stakeholders are extending their services arms to gain competitive edge. Market contributors in the global market should focus on effective and cost-efficient treatments for the patients. However, lack of awareness about the treatment and detection of PAH is expected to hamper the growth of the global pulmonary arterial hypertension (PAH) market during the forecast period.
Pulmonary arterial hypertension (PAH) is a rare and progressive disorder, characterized by high blood pressure in pulmonary arteries that carry blood from the heart to the lungs. PAH occurs when pulmonary arteries become narrow in diameter or get blocked. In the past few years, there has been an increasing prevalence of PAH disorder due to rising risk factors such as HIV, sedentary lifestyle, tobacco and alcohol consumption, smoking, and other idiopathic conditions. There are high-growth opportunities for market players in the near future due to increasing prevalence of PAH across the globe.
Various treatments are available in the market that helps in controlling and slowing down the growth of the diseases and improving the quality of life. In addition, the approval of few effective drugs and the occurrence of favorable pipeline are some of primary factors that drive the global market. Moreover, favorable policies by government has contributed in boosting the demand in the global pulmonary arterial hypertension market.
The increase in geriatric population in developing countries is expected to drive the global pulmonary arterial hypertension market in the upcoming years. The rising incidence of PAH in the geriatric population is driving the global pulmonary arterial hypertension market during the forecast period. Aging is one of the non-modifiable factors that increases the risk related to PAH. Elderly people are more susceptible to this disease due to diastolic dysfunction and age-associated blood vessel stiffening. Several educational programs have been initiated by key market contributors and governments to increase awareness about PAH among healthcare providers and patients. All these factors are expected to boost the global pulmonary arterial hypertension market over the next few years.
Technological advancements in drug discovery & development, along with rising research & development activities across the globe are driving the market. Based on drug class, the global pulmonary arterial hypertension (PAH) market has been classified into prostacyclin & prostacyclin analogs, PDE-5 inhibitors, ERAs (endothelin receptor antagonists), and soluble guanylate cyclase (sGC) stimulators. The prostacyclin & prostacyclin analogs segment is expected to dominate the market in the near future due to high demand. The SGC simulators segment is anticipated to grow at a rapid pace during the forecast period. sGC stimulators can ensure maximum activation of sGC by potentiating NO-sGC signaling. Riociguat (Adempas from Bayer) is the only drug approved for PAH in this category.
Geographically, North America is projected to dominate the global pulmonary arterial hypertension (PAH) market during the forecast period. North America is followed by Europe, and the market in both regions is projected to grow remarkably throughout the forecast period. This can be ascribed to the availability of commercialization of new PAH drugs coupled with a promising drug pipeline. In addition, growing awareness among people in both regions about the rising availability of treatment for pulmonary arterial hypertension is also pushing the market growth.
Moreover, Asia Pacific possess lucrative opportunities for the market players. Countries such as Japan, New Zealand, Australia, China, and India are projected to offer high growth opportunities attributing to growing penetration of global players.
|
Attribute |
Detail |
|
Market Size Value in 2020 |
US$ 5.2 Bn |
|
Market Forecast Value in 2028 |
US$ 13.5 Bn |
|
Growth Rate (CAGR) |
5.4% |
|
Forecast Period |
2021–2028 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
Pulmonary Arterial Hypertension (PAH) Market – Segmentation
| Attribute | Detail |
|---|---|
| Pipeline Analysis |
|
| Drug Class |
|
| Region |
|
It is expected to reach the value of US$ 13.5 Bn by the end of 2028
It is estimated to expand at a CAGR of 5.4% from 2021 to 2028
It is driven by increase in geriatric population in developing countries and rising incidence of PAH in the geriatric population
North America accounted for a major share of the global market during the forecast period
Key players in the global market include Actelion Pharmaceuticals, Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Pfizer, Inc., and United Therapeutics Corporation
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Pulmonary Arterial Hypertension (PAH) Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast, 2017-2028
5. Key Insights
5.1. Healthcare Industry Overview
5.2. Top 3 players operating in the market space
5.3. Technological Advancements
5.4. Key Mergers & Acquisitions
5.5. Disease Prevalence & Incidence Rate globally with key countries
5.6. COVID-19 Pandemics Impact on Industry (value chain and short / mid / long term impact)
6. Global Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017-2028
6.3.1. Prostacyclin & Prostacyclin Analogs
6.3.2. Endothelin Receptor Antagonists (ERAs)
6.3.3. Phosphodiesterase-5 (PDE-5) Inhibitors
6.3.4. Soluble Guanylate Cyclase (sGC) Stimulators
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast, by Pipeline Analysis
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Pipeline Analysis, 2017-2028
7.3.1. Early-stage Drug Candidates (Phase I & Phase II)
7.3.2. Late-stage Drug Candidates (Phase III & Registration Phase)
7.4. Market Attractiveness Analysis, by Pipeline Analysis
8. Global Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Country/Region
9. North America Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Drug Class, 2017-2028
9.2.1. Prostacyclin & Prostacyclin Analogs
9.2.2. Endothelin Receptor Antagonists (ERAs)
9.2.3. Phosphodiesterase-5 (PDE-5) Inhibitors
9.2.4. Soluble Guanylate Cyclase (sGC) Stimulators
9.3. Market Value Forecast, by Pipeline Analysis, 2017-2028
9.3.1. Early-stage Drug Candidates (Phase I & Phase II)
9.3.2. Late-stage Drug Candidates (Phase III & Registration Phase)
9.4. Market Value Forecast, by Country, 2017-2028
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Pipeline Analysis
9.5.3. By Country
10. Europe Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017-2028
10.2.1. Prostacyclin & Prostacyclin Analogs
10.2.2. Endothelin Receptor Antagonists (ERAs)
10.2.3. Phosphodiesterase-5 (PDE-5) Inhibitors
10.2.4. Soluble Guanylate Cyclase (sGC) Stimulators
10.3. Market Value Forecast, by Pipeline Analysis, 2017-2028
10.3.1. Early-stage Drug Candidates (Phase I & Phase II)
10.3.2. Late-stage Drug Candidates (Phase III & Registration Phase)
10.4. Market Value Forecast, by Country/Sub-region, 2017-2028
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Pipeline Analysis
10.5.3. By Country/Sub-region
11. Asia Pacific Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017-2028
11.2.1. Prostacyclin & Prostacyclin Analogs
11.2.2. Endothelin Receptor Antagonists (ERAs)
11.2.3. Phosphodiesterase-5 (PDE-5) Inhibitors
11.2.4. Soluble Guanylate Cyclase (sGC) Stimulators
11.3. Market Value Forecast, by Pipeline Analysis, 2017-2028
11.3.1. Early-stage Drug Candidates (Phase I & Phase II)
11.3.2. Late-stage Drug Candidates (Phase III & Registration Phase)
11.4. Market Value Forecast, by Country/Sub-region, 2017-2028
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Pipeline Analysis
11.5.3. By Country/Sub-region
12. Latin America Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017-2028
12.2.1. Prostacyclin & Prostacyclin Analogs
12.2.2. Endothelin Receptor Antagonists (ERAs)
12.2.3. Phosphodiesterase-5 (PDE-5) Inhibitors
12.2.4. Soluble Guanylate Cyclase (sGC) Stimulators
12.3. Market Value Forecast, by Pipeline Analysis, 2017-2028
12.3.1. Early-stage Drug Candidates (Phase I & Phase II)
12.3.2. Late-stage Drug Candidates (Phase III & Registration Phase)
12.4. Market Value Forecast, by Country/Sub-region, 2017-2028
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Pipeline Analysis
12.5.3. By Country/Sub-region
13. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017-2028
13.2.1. Prostacyclin & Prostacyclin Analogs
13.2.2. Endothelin Receptor Antagonists (ERAs)
13.2.3. Phosphodiesterase-5 (PDE-5) Inhibitors
13.2.4. Soluble Guanylate Cyclase (sGC) Stimulators
13.3. Market Value Forecast, by Pipeline Analysis, 2017-2028
13.3.1. Early-stage Drug Candidates (Phase I & Phase II)
13.3.2. Late-stage Drug Candidates (Phase III & Registration Phase)
13.4. Market Value Forecast, by Country/Sub-region, 2017-2028
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Pipeline Analysis
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2020
14.3. Company Profiles
14.3.1. Actelion Pharmaceuticals Ltd.
14.3.1.1. Company Overview (HQ, Business Segments, Employee)
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Strategic Overview
14.3.2. Gilead Sciences, Inc.
14.3.2.1. Company Overview (HQ, Business Segments, Employee)
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Strategic Overview
14.3.3. Pfizer, Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee)
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Strategic Overview
14.3.4. GlaxoSmithKline plc
14.3.4.1. Company Overview (HQ, Business Segments, Employee)
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Strategic Overview
14.3.5. United Therapeutics Corp
14.3.5.1. Company Overview (HQ, Business Segments, Employee)
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Strategic Overview
14.3.6. Novartis International AG
14.3.6.1. Company Overview (HQ, Business Segments, Employee)
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Strategic Overview
14.3.7. Bayer HealthCare
14.3.7.1. Company Overview (HQ, Business Segments, Employee)
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Strategic Overview
14.3.8. Other prominent players
14.3.8.1. Company Overview (HQ, Business Segments, Employee)
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Strategic Overview
List of Tables
Table 1: List of Abbreviations
Table 2: Market Snapshot: Global Pulmonary Arterial Hypertension Market (2017 & 2020)
Table 3: Annual Treatment Cost with Various PAH Drugs in the U.S.
Table 4: Event Impact Analysis: Global PAH Market
Table 5: Global Pulmonary Arterial Hypertension Market Revenue (US$ Mn), by Drug Class, 2017-2028
Table 6: Historical Sales Data: Prostacyclin & Prostacyclin Analog Brands
Table 7: Historical Sales Data: Endothelin Receptor Antagonist Brands
Table 8: Historical Sales Data: Phosphodiesterase 5 Inhibitor Brands
Table 9: Pulmonary Arterial Hypertension: Phase I & Phase II Molecules
Table 10: Global Pulmonary Arterial Hypertension Market Revenue (US$ Mn), by Geography, 2017-2028
Table 11: List of Major Countries in North America
Table 12: List of Major Countries in Europe
Table 13: List of Major Countries in Asia Pacific
Table 14: List of Major Countries in Latin America
Table 15: List of Major Countries in Middle East & Africa
List of Figures
Figure 1: Pulmonary Arterial Hypertension (PAH): Market Segmentation
Figure 2: Global Pulmonary Arterial Hypertension Market (US$ Mn), by Drug Class, 2019
Figure 3: Comparative Analysis: Global Pulmonary Arterial Hypertension Market Revenue (Value %), by Region, 2020 & 2028
Figure 4: Global Pulmonary Arterial Hypertension Market Share Analysis (Value %), by Key Players, 2020
Figure 5: Comparative Analysis: Global Pulmonary Arterial Hypertension Market Revenue, by Drug Class, 2020 & 2028 (Value %)
Figure 6: Global Prostacyclin & Prostacyclin Analogs Market Revenue (US$ Mn), 2017-2028
Figure 7: Global Endothelin Receptor Antagonists Market Revenue (US$ Mn), 2017-2028
Figure 8: Global Phosphodiesterase 5 Inhibitors Market Revenue (US$ Mn), 2017-2028
Figure 9: Global Soluble Guanylate Cyclase Stimulators Market Revenue (US$ Mn), 2017-2020
Figure 10: Major Steps: Drug Development and Commercialization
Figure 11: Global Uptravi (selexipag) Market Revenue (US$ Mn), 2017-2020
Figure 12: North America Pulmonary Arterial Hypertension Market Revenue (US$ Mn), 2017-2028
Figure 13: Europe Pulmonary Arterial Hypertension Market Revenue (US$ Mn), 2017-2028
Figure 14: Asia Pacific Pulmonary Arterial Hypertension Market Revenue (US$ Mn), 2017-2028
Figure 15: Latin America Pulmonary Arterial Hypertension Market Revenue (US$ Mn), 2017-2028
Figure 16: Middle East & Africa Pulmonary Arterial Hypertension Market Revenue (US$ Mn), 2017-2028
Figure 17: Actelion Pharmaceuticals, Ltd.: Annual Revenue (US$ Mn), 2017-2028
Figure 18: Bayer HealthCare: Annual Revenue (US$ Mn), 2017-2028
Figure 19: Gilead Sciences, Inc.: Annual Revenue (US$ Mn), 2017-2028
Figure 20: GlaxoSmithKline plc: Annual Revenue (US$ Mn), 2017-2028
Figure 21: Novartis International AG: Annual Revenue (US$ Mn), 2017-2028
Figure 22: Pfizer, Inc.: Annual Revenue (US$ Mn), 2017-2028
Figure 23: United Therapeutics Corporation: Annual Revenue (US$ Mn), 2017-2028
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Pulmonary Arterial Hypertension (PAH) Market
